APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Hypoglycemic Agents and Insulin Injection

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oral Hypoglycemic Agents and Insulin Injection Market Analysis and Forecast 2026-2032

30 December 2025217 pages

Choose your research edition.

Industry ResearchOral Hypoglycemic Agents and Insulin Injection Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Hypoglycemic Agents and Insulin Injection Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Oral Hypoglycemic Agents and Insulin Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Hypoglycemic Agents and Insulin Injection Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Hypoglycemic Agents and Insulin Injection Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Oral Hypoglycemic Agents and Insulin Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Oral Hypoglycemic Agents and Insulin Injection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oral Hypoglycemic Agents and Insulin Injection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oral Hypoglycemic Agents and Insulin Injection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oral Hypoglycemic Agents and Insulin Injection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Oral Hypoglycemic Agents and Insulin Injection include YZJ Group, Takeda Pharmaceuticals, Tonghua Dongbao Pharmaceutical, Sichuan Luye Pharma, Sanofi, Johnson & Johnson, Merck, The United Laboratories International Holdings and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Oral Hypoglycemic Agents and Insulin Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oral Hypoglycemic Agents and Insulin Injection, also provides the sales of main regions and countries. Of the upcoming market potential for Oral Hypoglycemic Agents and Insulin Injection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral Hypoglycemic Agents and Insulin Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oral Hypoglycemic Agents and Insulin Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Oral Hypoglycemic Agents and Insulin Injection sales, projected growth trends, production technology, application and end-user industry.

Oral Hypoglycemic Agents and Insulin Injection Segment by Company

YZJ Group

Takeda Pharmaceuticals

Tonghua Dongbao Pharmaceutical

Sichuan Luye Pharma

Sanofi

Johnson & Johnson

Merck

The United Laboratories International Holdings

Pfizer

Huadong Medicine

Gan and Lee Pharmaceuticals

AstraZeneca

Taisho Pharmaceutical

Servier Laboratories

Novo Nordisk

GlaxoSmithKline

Eli Lilly and Company

Chugai Pharmaceutical

Bristol Myers Squibb

Boehringer Ingelheim

Astellas

Oral Hypoglycemic Agents and Insulin Injection Segment by Type

Oral Hypoglycemic Agents

Insulin Injection

Oral Hypoglycemic Agents and Insulin Injection Segment by Application

E-commerce and Internet Medical Care

Offline Retail Pharmacy

Hospitals and Clinics

Oral Hypoglycemic Agents and Insulin Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Hypoglycemic Agents and Insulin Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Hypoglycemic Agents and Insulin Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Hypoglycemic Agents and Insulin Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Oral Hypoglycemic Agents and Insulin Injection in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Oral Hypoglycemic Agents and Insulin Injection manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Hypoglycemic Agents and Insulin Injection sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Hypoglycemic Agents Major Manufacturers Table 3. Insulin Injection Major Manufacturers Table 4. Global Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. E-commerce and Internet Medical Care Major Manufacturers Table 6. Offline Retail Pharmacy Major Manufacturers Table 7. Hospitals and Clinics Major Manufacturers Table 8. Oral Hypoglycemic Agents and Insulin Injection Industry Trends Table 9. Oral Hypoglycemic Agents and Insulin Injection Industry Drivers Table 10. Oral Hypoglycemic Agents and Insulin Injection Industry Opportunities and Challenges Table 11. Oral Hypoglycemic Agents and Insulin Injection Industry Restraints Table 12. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Region (2021-2026) Table 16. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Region (2027-2032) Table 17. Global Oral Hypoglycemic Agents and Insulin Injection Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (M Units) Table 18. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2021-2026) & (M Units) Table 19. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2027-2032) & (M Units) Table 20. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Region (2021-2026) Table 21. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Region (2027-2032) Table 22. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Manufacturers (2021-2026) Table 26. Global Oral Hypoglycemic Agents and Insulin Injection Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Oral Hypoglycemic Agents and Insulin Injection Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Oral Hypoglycemic Agents and Insulin Injection Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers, Product Type & Application Table 30. Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Oral Hypoglycemic Agents and Insulin Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Type (2021-2026) Table 37. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Type (2027-2032) Table 38. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type 2021 VS 2025 VS 2032 (M Units) Table 39. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 40. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2027-2032) & (M Units) Table 41. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Type (2021-2026) Table 42. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Type (2027-2032) Table 43. Global Oral Hypoglycemic Agents and Insulin Injection Price by Type (2021-2026) & (US$/Unit) Table 44. Global Oral Hypoglycemic Agents and Insulin Injection Price by Type (2027-2032) & (US$/Unit) Table 45. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Application (2021-2026) Table 49. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Application (2027-2032) Table 50. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application 2021 VS 2025 VS 2032 (M Units) Table 51. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 52. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2027-2032) & (M Units) Table 53. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Application (2021-2026) Table 54. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Application (2027-2032) Table 55. Global Oral Hypoglycemic Agents and Insulin Injection Price by Application (2021-2026) & (US$/Unit) Table 56. Global Oral Hypoglycemic Agents and Insulin Injection Price by Application (2027-2032) & (US$/Unit) Table 57. YZJ Group Company Information Table 58. YZJ Group Business Overview Table 59. YZJ Group Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. YZJ Group Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 61. YZJ Group Recent Development Table 62. Takeda Pharmaceuticals Company Information Table 63. Takeda Pharmaceuticals Business Overview Table 64. Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 66. Takeda Pharmaceuticals Recent Development Table 67. Tonghua Dongbao Pharmaceutical Company Information Table 68. Tonghua Dongbao Pharmaceutical Business Overview Table 69. Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 71. Tonghua Dongbao Pharmaceutical Recent Development Table 72. Sichuan Luye Pharma Company Information Table 73. Sichuan Luye Pharma Business Overview Table 74. Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 76. Sichuan Luye Pharma Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Sanofi Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 81. Sanofi Recent Development Table 82. Johnson & Johnson Company Information Table 83. Johnson & Johnson Business Overview Table 84. Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 86. Johnson & Johnson Recent Development Table 87. Merck Company Information Table 88. Merck Business Overview Table 89. Merck Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Merck Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 91. Merck Recent Development Table 92. The United Laboratories International Holdings Company Information Table 93. The United Laboratories International Holdings Business Overview Table 94. The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 96. The United Laboratories International Holdings Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Pfizer Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 101. Pfizer Recent Development Table 102. Huadong Medicine Company Information Table 103. Huadong Medicine Business Overview Table 104. Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 106. Huadong Medicine Recent Development Table 107. Gan and Lee Pharmaceuticals Company Information Table 108. Gan and Lee Pharmaceuticals Business Overview Table 109. Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 111. Gan and Lee Pharmaceuticals Recent Development Table 112. AstraZeneca Company Information Table 113. AstraZeneca Business Overview Table 114. AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 116. AstraZeneca Recent Development Table 117. Taisho Pharmaceutical Company Information Table 118. Taisho Pharmaceutical Business Overview Table 119. Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 121. Taisho Pharmaceutical Recent Development Table 122. Servier Laboratories Company Information Table 123. Servier Laboratories Business Overview Table 124. Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 126. Servier Laboratories Recent Development Table 127. Novo Nordisk Company Information Table 128. Novo Nordisk Business Overview Table 129. Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 131. Novo Nordisk Recent Development Table 132. GlaxoSmithKline Company Information Table 133. GlaxoSmithKline Business Overview Table 134. GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 136. GlaxoSmithKline Recent Development Table 137. Eli Lilly and Company Company Information Table 138. Eli Lilly and Company Business Overview Table 139. Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 141. Eli Lilly and Company Recent Development Table 142. Chugai Pharmaceutical Company Information Table 143. Chugai Pharmaceutical Business Overview Table 144. Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 146. Chugai Pharmaceutical Recent Development Table 147. Bristol Myers Squibb Company Information Table 148. Bristol Myers Squibb Business Overview Table 149. Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 151. Bristol Myers Squibb Recent Development Table 152. Boehringer Ingelheim Company Information Table 153. Boehringer Ingelheim Business Overview Table 154. Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 156. Boehringer Ingelheim Recent Development Table 157. Astellas Company Information Table 158. Astellas Business Overview Table 159. Astellas Oral Hypoglycemic Agents and Insulin Injection Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Astellas Oral Hypoglycemic Agents and Insulin Injection Product Portfolio Table 161. Astellas Recent Development Table 162. North America Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2026) & (US$ Million) Table 163. North America Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2027-2032) & (US$ Million) Table 164. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 165. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2027-2032) & (M Units) Table 166. North America Oral Hypoglycemic Agents and Insulin Injection Sales Price by Type (2021-2026) & (US$/Unit) Table 167. North America Oral Hypoglycemic Agents and Insulin Injection Sales Price by Type (2027-2032) & (US$/Unit) Table 168. North America Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2026) & (US$ Million) Table 169. North America Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2027-2032) & (US$ Million) Table 170. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 171. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2027-2032) & (M Units) Table 172. North America Oral Hypoglycemic Agents and Insulin Injection Sales Price by Application (2021-2026) & (US$/Unit) Table 173. North America Oral Hypoglycemic Agents and Insulin Injection Sales Price by Application (2027-2032) & (US$/Unit) Table 174. North America Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. North America Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 176. North America Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 177. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021 VS 2025 VS 2032) & (M Units) Table 178. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 179. North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2027-2032) & (M Units) Table 180. North America Oral Hypoglycemic Agents and Insulin Injection Sales Price by Country (2021-2026) & (US$/Unit) Table 181. North America Oral Hypoglycemic Agents and Insulin Injection Sales Price by Country (2027-2032) & (US$/Unit) Table 182. United States Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 183. Canada Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 184. Europe Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2026) & (US$ Million) Table 185. Europe Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2027-2032) & (US$ Million) Table 186. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 187. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2027-2032) & (M Units) Table 188. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Price by Type (2021-2026) & (US$/Unit) Table 189. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Price by Type (2027-2032) & (US$/Unit) Table 190. Europe Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2026) & (US$ Million) Table 191. Europe Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2027-2032) & (US$ Million) Table 192. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 193. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2027-2032) & (M Units) Table 194. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Price by Application (2021-2026) & (US$/Unit) Table 195. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Price by Application (2027-2032) & (US$/Unit) Table 196. Europe Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. Europe Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. Europe Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021 VS 2025 VS 2032) & (M Units) Table 200. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 201. Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2027-2032) & (M Units) Table 202. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Price by Country (2021-2026) & (US$/Unit) Table 203. Europe Oral Hypoglycemic Agents and Insulin Injection Sales Price by Country (2027-2032) & (US$/Unit) Table 204. Germany Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 205. France Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 206. U.K. Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 207. Italy Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 208. Netherlands Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 209. China Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2026) & (US$ Million) Table 210. China Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2027-2032) & (US$ Million) Table 211. China Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 212. China Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2027-2032) & (M Units) Table 213. China Oral Hypoglycemic Agents and Insulin Injection Sales Price by Type (2021-2026) & (US$/Unit) Table 214. China Oral Hypoglycemic Agents and Insulin Injection Sales Price by Type (2027-2032) & (US$/Unit) Table 215. China Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2026) & (US$ Million) Table 216. China Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2027-2032) & (US$ Million) Table 217. China Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 218. China Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2027-2032) & (M Units) Table 219. China Oral Hypoglycemic Agents and Insulin Injection Sales Price by Application (2021-2026) & (US$/Unit) Table 220. China Oral Hypoglycemic Agents and Insulin Injection Sales Price by Application (2027-2032) & (US$/Unit) Table 221. Asia Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2026) & (US$ Million) Table 222. Asia Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2027-2032) & (US$ Million) Table 223. Asia Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 224. Asia Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2027-2032) & (M Units) Table 225. Asia Oral Hypoglycemic Agents and Insulin Injection Sales Price by Type (2021-2026) & (US$/Unit) Table 226. Asia Oral Hypoglycemic Agents and Insulin Injection Sales Price by Type (2027-2032) & (US$/Unit) Table 227. Asia Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2026) & (US$ Million) Table 228. Asia Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2027-2032) & (US$ Million) Table 229. Asia Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 230. Asia Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2027-2032) & (M Units) Table 231. Asia Oral Hypoglycemic Agents and Insulin Injection Sales Price by Application (2021-2026) & (US$/Unit) Table 232. Asia Oral Hypoglycemic Agents and Insulin Injection Sales Price by Application (2027-2032) & (US$/Unit) Table 233. Asia Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 234. Asia Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 235. Asia Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 236. Asia Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021 VS 2025 VS 2032) & (M Units) Table 237. Asia Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 238. Asia Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2027-2032) & (M Units) Table 239. Asia Oral Hypoglycemic Agents and Insulin Injection Sales Price by Country (2021-2026) & (US$/Unit) Table 240. Asia Oral Hypoglycemic Agents and Insulin Injection Sales Price by Country (2027-2032) & (US$/Unit) Table 241. Japan Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 242. South Korea Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 243. India Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 244. Australia Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 245. China Taiwan Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 246. Southeast Asia Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 247. SAMEA Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2026) & (US$ Million) Table 248. SAMEA Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2027-2032) & (US$ Million) Table 249. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2026) & (M Units) Table 250. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2027-2032) & (M Units) Table 251. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales Price by Type (2021-2026) & (US$/Unit) Table 252. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales Price by Type (2027-2032) & (US$/Unit) Table 253. SAMEA Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2026) & (US$ Million) Table 254. SAMEA Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2027-2032) & (US$ Million) Table 255. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2026) & (M Units) Table 256. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2027-2032) & (M Units) Table 257. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales Price by Application (2021-2026) & (US$/Unit) Table 258. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales Price by Application (2027-2032) & (US$/Unit) Table 259. SAMEA Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 260. SAMEA Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 261. SAMEA Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 262. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021 VS 2025 VS 2032) & (M Units) Table 263. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021-2026) & (M Units) Table 264. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2027-2032) & (M Units) Table 265. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales Price by Country (2021-2026) & (US$/Unit) Table 266. SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales Price by Country (2027-2032) & (US$/Unit) Table 267. Brazil Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 268. Argentina Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 269. Chile Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 270. Colombia Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 271. Peru Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 272. Saudi Arabia Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 273. Israel Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 274. UAE Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 275. Turkey Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 276. Iran Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 277. Egypt Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Table 278. Key Raw Materials Table 279. Raw Materials Key Suppliers Table 280. Oral Hypoglycemic Agents and Insulin Injection Distributors List Table 281. Oral Hypoglycemic Agents and Insulin Injection Customers List Table 282. Research Programs/Design for This Report Table 283. Authors List of This Report Table 284. Secondary Sources Table 285. Primary Sources List of Figures Figure 1. Oral Hypoglycemic Agents and Insulin Injection Image Figure 2. Global Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Hypoglycemic Agents and Insulin Injection Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Hypoglycemic Agents Image Figure 5. Insulin Injection Image Figure 6. Global Oral Hypoglycemic Agents and Insulin Injection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Oral Hypoglycemic Agents and Insulin Injection Market Size Share 2021 VS 2025 VS 2032 Figure 8. E-commerce and Internet Medical Care Image Figure 9. Offline Retail Pharmacy Image Figure 10. Hospitals and Clinics Image Figure 11. Global Oral Hypoglycemic Agents and Insulin Injection Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Oral Hypoglycemic Agents and Insulin Injection Revenue (2021-2032) & (US$ Million) Figure 13. Global Oral Hypoglycemic Agents and Insulin Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Region (2021-2032) Figure 16. Global Oral Hypoglycemic Agents and Insulin Injection Sales (2021-2032) & (M Units) Figure 17. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region: 2021 VS 2025 VS 2032 (M Units) Figure 18. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Oral Hypoglycemic Agents and Insulin Injection Sales YoY (2021-2032) & (M Units) Figure 20. Europe Oral Hypoglycemic Agents and Insulin Injection Sales YoY (2021-2032) & (M Units) Figure 21. China Oral Hypoglycemic Agents and Insulin Injection Sales YoY (2021-2032) & (M Units) Figure 22. Asia (Excluding China) Oral Hypoglycemic Agents and Insulin Injection Sales YoY (2021-2032) & (M Units) Figure 23. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Injection Sales YoY (2021-2032) & (M Units) Figure 24. Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Type (2021-2032) Figure 30. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021 VS 2025 VS 2032) & (M Units) Figure 31. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Type (2021-2032) Figure 33. Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Application (2021-2032) Figure 36. Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021 VS 2

Scope & coverage.

Types
  • Oral Hypoglycemic Agents
  • Insulin Injection
Applications
  • E-commerce and Internet Medical Care
  • Offline Retail Pharmacy
  • Hospitals and Clinics
Companies covered
  • YZJ Group
  • Takeda Pharmaceuticals
  • Tonghua Dongbao Pharmaceutical
  • Sichuan Luye Pharma
  • Sanofi
  • Johnson & Johnson
  • Merck
  • The United Laboratories International Holdings
  • Pfizer
  • Huadong Medicine
  • Gan and Lee Pharmaceuticals
  • AstraZeneca
  • Taisho Pharmaceutical
  • Servier Laboratories
  • Novo Nordisk
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Chugai Pharmaceutical
  • Bristol Myers Squibb
  • Boehringer Ingelheim
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oral Hypoglycemic Agents and Insulin Injection Market by Type
  3. 1.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral Hypoglycemic Agents
  5. 1.2.3 Insulin Injection
  6. 1.3 Oral Hypoglycemic Agents and Insulin Injection Market by Application
  7. 1.3.1 Global Oral Hypoglycemic Agents and Insulin Injection Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 E-commerce and Internet Medical Care
  9. 1.3.3 Offline Retail Pharmacy
  10. 1.3.4 Hospitals and Clinics
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Oral Hypoglycemic Agents and Insulin Injection Market Dynamics
  1. 2.1 Oral Hypoglycemic Agents and Insulin Injection Industry Trends
  2. 2.2 Oral Hypoglycemic Agents and Insulin Injection Industry Drivers
  3. 2.3 Oral Hypoglycemic Agents and Insulin Injection Industry Opportunities and Challenges
  4. 2.4 Oral Hypoglycemic Agents and Insulin Injection Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region
  3. 3.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region (2021-2026)
  5. 3.2.3 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Region (2027-2032)
  6. 3.2.4 Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Oral Hypoglycemic Agents and Insulin Injection Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region
  9. 3.4.1 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2021-2026)
  11. 3.4.3 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Region (2027-2032)
  12. 3.4.4 Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Manufacturers
  2. 4.1.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Manufacturers
  6. 4.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Oral Hypoglycemic Agents and Insulin Injection Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Oral Hypoglycemic Agents and Insulin Injection Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Oral Hypoglycemic Agents and Insulin Injection Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers, Product Type & Application
  13. 4.7 Global Oral Hypoglycemic Agents and Insulin Injection Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Oral Hypoglycemic Agents and Insulin Injection Market CR5 and HHI
  16. 4.8.2 2025 Oral Hypoglycemic Agents and Insulin Injection Tier 1, Tier 2, and Tier 3
5 Oral Hypoglycemic Agents and Insulin Injection Market by Type
  1. 5.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type
  2. 5.1.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type
  6. 5.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2032) & (M Units)
  8. 5.2.3 Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Type (2021-2032)
  9. 5.3 Global Oral Hypoglycemic Agents and Insulin Injection Price by Type
6 Oral Hypoglycemic Agents and Insulin Injection Market by Application
  1. 6.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application
  2. 6.1.1 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Oral Hypoglycemic Agents and Insulin Injection Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application
  6. 6.2.1 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2032) & (M Units)
  8. 6.2.3 Global Oral Hypoglycemic Agents and Insulin Injection Sales Market Share by Application (2021-2032)
  9. 6.3 Global Oral Hypoglycemic Agents and Insulin Injection Price by Application
7 Company Profiles
  1. 7.1 YZJ Group
  2. 7.1.1 YZJ Group Company Information
  3. 7.1.2 YZJ Group Business Overview
  4. 7.1.3 YZJ Group Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 YZJ Group Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  6. 7.1.5 YZJ Group Recent Developments
  7. 7.2 Takeda Pharmaceuticals
  8. 7.2.1 Takeda Pharmaceuticals Company Information
  9. 7.2.2 Takeda Pharmaceuticals Business Overview
  10. 7.2.3 Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  12. 7.2.5 Takeda Pharmaceuticals Recent Developments
  13. 7.3 Tonghua Dongbao Pharmaceutical
  14. 7.3.1 Tonghua Dongbao Pharmaceutical Company Information
  15. 7.3.2 Tonghua Dongbao Pharmaceutical Business Overview
  16. 7.3.3 Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Tonghua Dongbao Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  18. 7.3.5 Tonghua Dongbao Pharmaceutical Recent Developments
  19. 7.4 Sichuan Luye Pharma
  20. 7.4.1 Sichuan Luye Pharma Company Information
  21. 7.4.2 Sichuan Luye Pharma Business Overview
  22. 7.4.3 Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Sichuan Luye Pharma Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  24. 7.4.5 Sichuan Luye Pharma Recent Developments
  25. 7.5 Sanofi
  26. 7.5.1 Sanofi Company Information
  27. 7.5.2 Sanofi Business Overview
  28. 7.5.3 Sanofi Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  30. 7.5.5 Sanofi Recent Developments
  31. 7.6 Johnson & Johnson
  32. 7.6.1 Johnson & Johnson Company Information
  33. 7.6.2 Johnson & Johnson Business Overview
  34. 7.6.3 Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Johnson & Johnson Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  36. 7.6.5 Johnson & Johnson Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Merck Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 The United Laboratories International Holdings
  44. 7.8.1 The United Laboratories International Holdings Company Information
  45. 7.8.2 The United Laboratories International Holdings Business Overview
  46. 7.8.3 The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 The United Laboratories International Holdings Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  48. 7.8.5 The United Laboratories International Holdings Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 Huadong Medicine
  56. 7.10.1 Huadong Medicine Company Information
  57. 7.10.2 Huadong Medicine Business Overview
  58. 7.10.3 Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Huadong Medicine Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  60. 7.10.5 Huadong Medicine Recent Developments
  61. 7.11 Gan and Lee Pharmaceuticals
  62. 7.11.1 Gan and Lee Pharmaceuticals Company Information
  63. 7.11.2 Gan and Lee Pharmaceuticals Business Overview
  64. 7.11.3 Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Gan and Lee Pharmaceuticals Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  66. 7.11.5 Gan and Lee Pharmaceuticals Recent Developments
  67. 7.12 AstraZeneca
  68. 7.12.1 AstraZeneca Company Information
  69. 7.12.2 AstraZeneca Business Overview
  70. 7.12.3 AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 AstraZeneca Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  72. 7.12.5 AstraZeneca Recent Developments
  73. 7.13 Taisho Pharmaceutical
  74. 7.13.1 Taisho Pharmaceutical Company Information
  75. 7.13.2 Taisho Pharmaceutical Business Overview
  76. 7.13.3 Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Taisho Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  78. 7.13.5 Taisho Pharmaceutical Recent Developments
  79. 7.14 Servier Laboratories
  80. 7.14.1 Servier Laboratories Company Information
  81. 7.14.2 Servier Laboratories Business Overview
  82. 7.14.3 Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Servier Laboratories Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  84. 7.14.5 Servier Laboratories Recent Developments
  85. 7.15 Novo Nordisk
  86. 7.15.1 Novo Nordisk Company Information
  87. 7.15.2 Novo Nordisk Business Overview
  88. 7.15.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Novo Nordisk Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  90. 7.15.5 Novo Nordisk Recent Developments
  91. 7.16 GlaxoSmithKline
  92. 7.16.1 GlaxoSmithKline Company Information
  93. 7.16.2 GlaxoSmithKline Business Overview
  94. 7.16.3 GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 GlaxoSmithKline Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  96. 7.16.5 GlaxoSmithKline Recent Developments
  97. 7.17 Eli Lilly and Company
  98. 7.17.1 Eli Lilly and Company Company Information
  99. 7.17.2 Eli Lilly and Company Business Overview
  100. 7.17.3 Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Eli Lilly and Company Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  102. 7.17.5 Eli Lilly and Company Recent Developments
  103. 7.18 Chugai Pharmaceutical
  104. 7.18.1 Chugai Pharmaceutical Company Information
  105. 7.18.2 Chugai Pharmaceutical Business Overview
  106. 7.18.3 Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Chugai Pharmaceutical Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  108. 7.18.5 Chugai Pharmaceutical Recent Developments
  109. 7.19 Bristol Myers Squibb
  110. 7.19.1 Bristol Myers Squibb Company Information
  111. 7.19.2 Bristol Myers Squibb Business Overview
  112. 7.19.3 Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Bristol Myers Squibb Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  114. 7.19.5 Bristol Myers Squibb Recent Developments
  115. 7.20 Boehringer Ingelheim
  116. 7.20.1 Boehringer Ingelheim Company Information
  117. 7.20.2 Boehringer Ingelheim Business Overview
  118. 7.20.3 Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Boehringer Ingelheim Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  120. 7.20.5 Boehringer Ingelheim Recent Developments
  121. 7.21 Astellas
  122. 7.21.1 Astellas Company Information
  123. 7.21.2 Astellas Business Overview
  124. 7.21.3 Astellas Oral Hypoglycemic Agents and Insulin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Astellas Oral Hypoglycemic Agents and Insulin Injection Product Portfolio
  126. 7.21.5 Astellas Recent Developments
8 North America
  1. 8.1 North America Oral Hypoglycemic Agents and Insulin Injection Market Size by Type
  2. 8.1.1 North America Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2032)
  3. 8.1.2 North America Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2032)
  4. 8.1.3 North America Oral Hypoglycemic Agents and Insulin Injection Price by Type (2021-2032)
  5. 8.2 North America Oral Hypoglycemic Agents and Insulin Injection Market Size by Application
  6. 8.2.1 North America Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2032)
  7. 8.2.2 North America Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2032)
  8. 8.2.3 North America Oral Hypoglycemic Agents and Insulin Injection Price by Application (2021-2032)
  9. 8.3 North America Oral Hypoglycemic Agents and Insulin Injection Market Size by Country
  10. 8.3.1 North America Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Oral Hypoglycemic Agents and Insulin Injection Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Oral Hypoglycemic Agents and Insulin Injection Market Size by Type
  2. 9.1.1 Europe Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2032)
  3. 9.1.2 Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2032)
  4. 9.1.3 Europe Oral Hypoglycemic Agents and Insulin Injection Price by Type (2021-2032)
  5. 9.2 Europe Oral Hypoglycemic Agents and Insulin Injection Market Size by Application
  6. 9.2.1 Europe Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2032)
  7. 9.2.2 Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2032)
  8. 9.2.3 Europe Oral Hypoglycemic Agents and Insulin Injection Price by Application (2021-2032)
  9. 9.3 Europe Oral Hypoglycemic Agents and Insulin Injection Market Size by Country
  10. 9.3.1 Europe Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Oral Hypoglycemic Agents and Insulin Injection Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Oral Hypoglycemic Agents and Insulin Injection Market Size by Type
  2. 10.1.1 China Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2032)
  3. 10.1.2 China Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2032)
  4. 10.1.3 China Oral Hypoglycemic Agents and Insulin Injection Price by Type (2021-2032)
  5. 10.2 China Oral Hypoglycemic Agents and Insulin Injection Market Size by Application
  6. 10.2.1 China Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2032)
  7. 10.2.2 China Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2032)
  8. 10.2.3 China Oral Hypoglycemic Agents and Insulin Injection Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oral Hypoglycemic Agents and Insulin Injection Market Size by Type
  2. 11.1.1 Asia Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2032)
  3. 11.1.2 Asia Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2032)
  4. 11.1.3 Asia Oral Hypoglycemic Agents and Insulin Injection Price by Type (2021-2032)
  5. 11.2 Asia Oral Hypoglycemic Agents and Insulin Injection Market Size by Application
  6. 11.2.1 Asia Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2032)
  7. 11.2.2 Asia Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2032)
  8. 11.2.3 Asia Oral Hypoglycemic Agents and Insulin Injection Price by Application (2021-2032)
  9. 11.3 Asia Oral Hypoglycemic Agents and Insulin Injection Market Size by Country
  10. 11.3.1 Asia Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Oral Hypoglycemic Agents and Insulin Injection Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oral Hypoglycemic Agents and Insulin Injection Market Size by Type
  2. 12.1.1 SAMEA Oral Hypoglycemic Agents and Insulin Injection Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Oral Hypoglycemic Agents and Insulin Injection Price by Type (2021-2032)
  5. 12.2 SAMEA Oral Hypoglycemic Agents and Insulin Injection Market Size by Application
  6. 12.2.1 SAMEA Oral Hypoglycemic Agents and Insulin Injection Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Oral Hypoglycemic Agents and Insulin Injection Price by Application (2021-2032)
  9. 12.3 SAMEA Oral Hypoglycemic Agents and Insulin Injection Market Size by Country
  10. 12.3.1 SAMEA Oral Hypoglycemic Agents and Insulin Injection Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Oral Hypoglycemic Agents and Insulin Injection Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Oral Hypoglycemic Agents and Insulin Injection Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Oral Hypoglycemic Agents and Insulin Injection Value Chain Analysis
  2. 13.1.1 Oral Hypoglycemic Agents and Insulin Injection Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Oral Hypoglycemic Agents and Insulin Injection Production Mode & Process
  6. 13.2 Oral Hypoglycemic Agents and Insulin Injection Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Oral Hypoglycemic Agents and Insulin Injection Distributors
  9. 13.2.3 Oral Hypoglycemic Agents and Insulin Injection Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst